Thumbs up from international guidelines1-8
and from patients Sarah, Bob, and Minnie
- THIS CONTENT IS FOR HEALTHCARE PROFESSIONALS ONLY -
Contents
Thumbs up from the international guidelines
International guidelines1-8 encourage health professionals to consider plant stanol ester, the functional ingredient in Benecol® foods and food supplements, as part of the management of raised cholesterol especially for the following three patient groups:
-
Individuals with high LDL cholesterol at low or intermediate cardiovascular risk who do not qualify for statin therapy
-
High and very high risk patients, such as patients with diabetes, who fail to reach their LDL-cholesterol targets on statins alone, or are statin intolerant
-
Adults and children with familial hypercholesterolemia
When consumed in sufficient amounts as part of daily meals plant stanol ester lowers LDL cholesterol in 2-3 weeks by 10%, on average, and keeps it at the lower level.
So when helping your patients to manage their cholesterol, adding Benecol® foods or food supplements to their diets is the right thing to do.
Meet the patients and watch their stories below.
Patient Sarah
Sarah is a 39-year-old sales manager, non-smoker and physically moderately active. At a recent health check she found out that she had elevated blood LDL-cholesterol.
Patient Bob
Bob is a 46-year-old teacher with type 2 diabetes and hypercholesterolemia diagnosed four years ago at a routine health check.
Patient Minnie
Minnie is a 7-year-old girl who was recently diagnosed with familial hypercholesterolemia.
References
- Gylling et al. EAS Consensus Paper. Plant sterols and plant stanols in the management of dyslipidaemia and prevention of cardiovascular disease. Atherosclerosis 2014; 232: 346-360. http://www.atherosclerosis-journal.com/article/S0021-9150(13)00694-1/pdf
- Catapano et al. 2016 ESC/EAS Guidelines for the management of dyslipidaemias. Atherosclerosis 2016; 253: 281-344. http://www.atherosclerosis-journal.com/article/S0021-9150(16)31267-9/pdf
- Piepoli et al. 2016 European Guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J 2016; 37: 2315–2381. http://eurheartj.oxfordjournals.org/content/ehj/37/29/2315.full.pdf
- International Atherosclerosis Society. IAS Position Paper: Global Recommendations for the Management of Dyslipidemia, 2013. http://www.athero.org/IASPositionPaper.asp
- American Diabetes Association. Cardiovascular disease and risk management. Sec. 8. In Standards of Medical Care in Diabetes 2016. Diabetes Care 2016; 39: S60–S71. http://care.diabetesjournals.org/content/diacare/39/Supplement_1/S60.full.pdf
- Expert Panel on Integrated Guidelines for Cardiovascular Health and Risk Reduction in Children and Adolescents: Summary Report. Pediatrics 2011; 128: S213 -S256. https://www.nhlbi.nih.gov/files/docs/peds_guidelines_sum.pdf
- Nordestgaard et al. EAS Consensus Paper. Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease Eur Heart J 2013; 34 (45): 3478-3490. http://eurheartj.oxfordjournals.org/content/ehj/34/45/3478.full.pdf
- Stroes et al. EAS Consensus Paper. Statin-associated muscle symptoms: impact on statin therapy—European Atherosclerosis Society Consensus Panel Statement on Assessment, Aetiology and Management. Eur Heart J 2015; 36 (17): 1012-1022. http://eurheartj.oxfordjournals.org/content/ehj/36/17/1012.full.pdf